Health Condition 1: D50-D89- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism Health Condition 2: D70-D77- Other disorders of blood and blood-forming organs Health Condition 3: D72- Other disorders of white blood cells Health Condition 4: D728- Other specified disorders of whiteblood cells
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Indian Council Of Medical Research
Eligibility
Inclusion criteria
Inclusion criteria: Male or female aged = 18 years Diagnosis of CML: Any patient who is planned for TKI or already taking TKI
Exclusion criteria
Exclusion criteria: Another active malignancy at the time of diagnosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quantitative and Qualitative analysis of PBMC in different phase of CML patients using Molecular Techniques. Identification of disease relevant phospho-signature in TKI therapy sensitive and resistant CML patients. Timepoint: The non-responders patients will have 3 data points at 0, 3, and 18 months while the sensitive patients will have two data points at 0 and 3 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Interrogative signaling pathway analysis utilizing newly developed phospho-PRM assay. Dose- dependent analysis and validation of newly developed assay in large cohort of CML patient samples. Timepoint: The non-responders patients will have 3 data points at 0, 3, and 18 months while the sensitive patients will have two data points at 0 and 3 months. | — |
Countries
India
Contacts
Public ContactDr Atul Thatai
Max Super Speciality Hospital, Vaishali (A Unit of Crosslay Remedies Ltd.)
Outcome results
None listed